RS-2025-02213480

EGFR-Targeted p53 mRNA-Based Head and Neck Cancer Therapy

Sungkyunkwan University(Research Business Foundation)
SUNG KYUN KWAN UNIVERSITY(SKKU)

ONCOLOGY | **Hit**

Product Type	Gene/Cell Therapy & Nucleic acids
Indication	Head and neck cancer
Target	EGFR
MoA(Mechanism of Action)	(1) Elimination of mutant p53 and simultaneous reactivation of wild-type p53 (2) mRNA@LNP platform for EGFR-targeted delivery (3) Synergistic apoptosis-enhancing technology (Radiotherapy & Apoptosis mRNA) (4) Development of an effective cancer treatment strategy that reduces side effects through Low-Dose Radiation 
Competitiveness	• A novel therapeutic option for Hard-to-Cure head and neck cancers and EGFR-overexpressing tumors • Maximization of radiotherapy efficacy through microenvironment modulation via precision delivery of p53 mRNA • Significant reduction of radiation-related side effects by lowering the radiation dose without compromising efficacy • Enhancement of LNP production efficiency for targeted RNA delivery via a streamlined and scalable process • Potential for broad applicability across multiple tumor types
Development Stage	Hit
Route of Administration	IV